Browse studies

Find your next paid study

7 recruiting studies matching your filters

A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment

The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD…

HIV -1 Infection

Estimated

~$10 – $7,500

Gilead SciencesNCT07719491

Phase 1

Phase 1 Randomized Double-Blind Placebo-Controlled Safety Study of MucoCept-CVN (Lactobacillus Jensenii 1153-1666) Administered Vaginally to Healthy Women

MucoCept-CVN uses a Lactobacillus strain native to the human vagina that is modified into a live biotherapeutic product (LBP) that continuously expresses a pot…

HIV -1 Infection

Estimated

~$10 – $7,500

Craig Cohen, MD, MPHNCT07181486

Phase 4

A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate the Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pa…

HIV -1 InfectionHIV (Human Immunodeficiency Virus)HIV+1 more

Estimated

~$10 – $7,500

CAN Community HealthNCT07476339

Phase 1

A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV

This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV). This study will a…

HIV -1 Infection

Estimated

~$10 – $7,500

BioNTech SENCT07392372

Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women With HIV in the United States

Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) du…

HIV -1 Infection

Estimated

~$10 – $750

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupNCT07637942

Phase 1

A Randomized, Placebo-controlled, Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity, and Impact on Virological Control of the Investigational RNA-based Vaccine BNT168 in Adults Living With or Without HIV

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see…

HIV -1 Infection

Estimated

~$10 – $7,500

BioNTech SENCT07698600

Phase 4

Short-term Effects of Methamphetamine on Residual Latent HIV Disease (EMRLHD) Study

The most commonly used illicit stimulant in people with HIV (PWH) is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased…

HIV -1 InfectionMethamphetamine Use

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07584369